What is Stem Cell PRP Therapy?
Operating under the brand Relievus, the company serves as a specialized provider of regenerative medicine, focusing on the intersection of stem cell therapy and platelet-rich plasma (PRP) treatments. The firm distinguishes itself through a multidisciplinary approach, integrating board-certified pain specialists, neurologists, and physiatrists to address chronic pain conditions such as arthritis. By utilizing the body's intrinsic healing mechanisms, the company provides a non-invasive alternative to traditional pain management, effectively bridging the gap between conventional neurology and advanced orthobiologics. Their presence in New Jersey and Pennsylvania serves as a foundational base for scaling these high-demand medical services.
How much funding has Stem Cell PRP Therapy raised?
Stem Cell PRP Therapy has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Stem Cell PRP Therapy
PPP
Public-Private Partnership
What's next for Stem Cell PRP Therapy?
With the infusion of this late-stage capital, Stem Cell PRP Therapy is expected to prioritize the expansion of its clinical infrastructure and the optimization of its patient care delivery models. The strategic focus will likely shift toward increasing market penetration in the Mid-Atlantic region while potentially investing in clinical research to further validate the efficacy of their regenerative protocols. As the company matures, the integration of advanced diagnostic technologies and the scaling of their specialized medical team will be critical to maintaining their competitive advantage in the rapidly evolving landscape of pain management and regenerative healthcare.
See full Stem Cell PRP Therapy company page
